CluePoints
CluePoints is recorded as a service provider in 51 clinical trials. Explore its recorded services, study phases and therapeutic areas, with trial-level operational learnings where available.
Clinical trial experience
Showing 20 of 51 trials · Latest update first
An open-label, single-arm study evaluating the activity, safety, and pharmacokinetics of rozanolixizumab in pediatric study participants with moderate to severe generalized myasthenia gravis
Sponsor UCB Biopharma
- Start (EU)
- Latest update
- Estimated end
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants
Sponsor Ipsen Innovation
- Start (EU)
- Latest update
- Estimated end
Phase 3, Multicenter, Randomized, Double-Masked, Vehicle-Controlled, Parallel Group Study to Evaluate the Safety and Efficacy of Recombinant Human Nerve Growth Factor Eye Drop Solution in Participants With Persistent Corneal Epithelial Defect (PCED)
Sponsor Dompe' Farmaceutici S.p.A.
- Start (EU)
- Latest update
- Estimated end
A Phase 3, Multicenter, Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Safety and Efficacy of L606 (Treprostinil Liposome Inhalation Suspension) in Participants with Pulmonary Hypertension Associated with Interstitial Lung Disease (WHO Group 3)
Sponsor Liquidia Technologies Inc.
- Start (EU)
- Latest update
- Estimated end
A Phase III randomised, double-blind, multicentre study to compare the efficacy, safety, pharmacokinetics, and immunogenicity between SB27 (proposed pembrolizumab biosimilar) and Keytruda in subjects with metastatic non-squamous non-small cell lung cancer
Sponsor Samsung Bioepis Co. Ltd.
- Start (EU)
- Latest update
- Estimated end
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Parallel Study to Evaluate the Efficacy and Safety of Enpatoran in Participants with Active Cutaneous Manifestations of Lupus Erythematosus With or Without Systemic Disease Receiving Standard of Care
Sponsor Merck Healthcare KGaA
- Start (EU)
- Latest update
- Estimated end
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Parallel Study to Evaluate the Efficacy and Safety of Enpatoran in Participants with Active Cutaneous Manifestations of Lupus Erythematosus With or Without Systemic Disease Receiving Standard of Care
Sponsor Merck Healthcare KGaA
- Start (EU)
- Latest update
- Estimated end
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicentre, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport® for the Prevention of Episodic Migraine in Adult Participants
Sponsor Ipsen Innovation
- Start (EU)
- Latest update
- Estimated end
A Phase 2, randomized, placebo-controlled, double-blind clinical study to evaluate efficacy and safety of LAD603 in adult subjects with severe to very severe alopecia areata
Sponsor Almirall S.A.
- Start (EU)
- Latest update
- Estimated end
A randomized, double-blind, placebo-controlled, parallel-group, Proof-of-Concept (PoC) study to assess the efficacy, safety and tolerability of itepekimab, in participants with non-cystic fibrosis bronchiectasis
Sponsor Sanofi-Aventis Recherche & Developpement
- Start (EU)
- Latest update
- Estimated end
Operational learnings available4 trial-level findings · Read insights
- The study enrolled 314 participants at 117 sites in 20 countries between 20 February 2024 and 7 March 2025.
- Of 386 screened participants, 72 were screen failures because they did not meet eligibility criteria.
- A January 2024 protocol amendment revised the pulmonary-exacerbation endpoint definition following health-authority feedback and added adjudication of moderate or severe pulmonary exacerbations.
- Few scheduled site visits for sample collection were missed, and only participants with data at the specified time points were reported for spirometry and pharmacokinetic analyses.
These findings describe the trial, not the service provider’s performance or responsibility.
Trial title: Phase 1b/3 global, randomized, controlled, open-label trial comparing treatment with RYZ101 to standard of care (SoC) therapy in subjects with inoperable, advanced, somatostatin receptor expressing (SSTR+), well-differentiated gastro-enteropancreatic neuroendocrine tumors (GEP-NETs) that have progressed following prior 177Lu-labelled somatostatin analogue (177Lu-SSA) therapy (ACTION-1)
Sponsor Rayzebio Inc.
- Start (EU)
- Latest update
- Estimated end
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Proof of Concept (POC) Study Evaluating the Safety, Tolerability, and Efficacy of Nintedanib Solution for Inhalation (AP02) in Participants with Idiopathic Pulmonary Fibrosis (IPF) (AURA-IPF)
Sponsor Avalyn Pharma Inc.
- Start (EU)
- Latest update
- Estimated end
A Randomized, Placebo-Controlled, Double-Blind, Multicenter, Phase 2 Study to Assess the Efficacy and Safety of Daily OM-85 Treatment vs. Placebo given in Children Aged 6 Months to 5 Years with Recurrent Wheezing
Sponsor OM Pharma SA
- Start (EU)
- Latest update
- Estimated end
PROCEADE PanTumor: A Phase 1b/2, Multicenter, Open Label Study of Anti-CEACAM5 Antibody-Drug Conjugate Precemtabart Tocentecan (M9140) in Participants With Advanced Pancreatic Cancer (Substudy PDAC)
Sponsor Merck Healthcare KGaA
- Start (EU)
- Latest update
- Estimated end
A Randomized, Open Label, 3-arm Phase 3 Study of Precemtabart Tocentecan with or Without Bevacizumab Compared to Trifluridine/Tipiracil plus Bevacizumab in Participants with Previously Treated Metastatic Colorectal Cancer (PROCEADE-CRC-03)
Sponsor Merck Healthcare KGaA
- Start (EU)
- Latest update
- Estimated end
PROCEADE PanTumor: A Phase 1b/2, Multicenter, Open-Label Study of Anti-CEACAM5 Antibody-Drug Conjugate Precemtabart Tocentecan (M9140) in Participants With Advanced Gastric Cancer (Substudy GC)
Sponsor Merck Healthcare KGaA
- Start (EU)
- Latest update
- Estimated end
A phase 3, multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to R-CHOP versus R CHOP in previously untreated, high-intermediate and high-risk patients with newly-diagnosed diffuse large B-cell lymphoma (DLBCL) [frontMIND]
Sponsor Incyte Corp.
- Start (EU)
- Latest update
- Estimated end
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Revumenib in Combination with Intensive Chemotherapy in Participants with Newly Diagnosed AML with an NPM1 mutation (REVEAL-ND NPM1)
Sponsor Syndax Pharmaceuticals Inc.
- Start (EU)
- Latest update
- Estimated end
A Phase 3, multicentre, randomised (1:1), parallel-group, active-controlled, central reader colonoscopist-blind study to evaluate the bowel cleansing efficacy, safety, tolerability, palatability, and acceptability of PLENVU® as compared to sodium picosulfate in paediatric participants from 1 to < 18 years of age in preparation for colonoscopy (CLARITY)
Sponsor Norgine Limited
- Start (EU)
- Latest update
- Estimated end
An open-label extension study to evaluate rozanolixizumab in pediatric study participants with generalized myasthenia gravis
Sponsor UCB Biopharma
- Start (EU)
- Latest update
- Estimated end
Questions about this trial experience
What services are recorded for CluePoints?
The 2026-10-09 snapshot links CluePoints to 51 distinct CTIS trials. Recorded services include Data management, Centralized data monitoring, Central Monitoring system, Data Surveillance, among 34 recorded service labels. These are study-specific roles, not a complete or independently verified capability catalogue.
Which therapeutic areas and study phases are recorded for CluePoints?
The most frequently recorded therapeutic areas are Immunology, Gastroenterology, Respiratory, Solid Tumor Oncology. Recorded phases include Phase 3, Phase 2, Phase 1. Use the filters to inspect the supporting studies; missing tags are not evidence of absent experience.
In which countries are trials linked to CluePoints conducted?
The linked trials record locations in 23 countries, including Poland, Germany, Spain, Italy, France. These are trial locations, not confirmed office locations or countries where CluePoints delivered services.
What can this page tell me about CluePoints's trial experience?
Browse 51 distinct trials with recorded roles, sponsor names, available study dates and links to CTIS source records. 1 trials have operational findings that can inform further due diligence. Trial counts and findings do not measure the provider’s performance or establish responsibility for study outcomes.
About this data & company names
One current approved profile per CTIS trial. Services reflect recorded roles, not a complete capability catalogue or a performance ranking. Missing tags mean the information was not recorded. Country tags describe trial locations, not the provider’s service territory.
Start is the reported EU start date; latest update is the CTIS publication date; estimated end is the reported global estimate, which may be in the past. Missing dates are shown as “Not reported”. Operational learnings describe the trial as a whole and do not establish the provider’s responsibility.
Clear service synonyms are grouped; otherwise the source label is retained. Service tags show the recorded roles for each trial. This page groups 4 recorded name variants under CluePoints. Legacy brands remain separate unless explicitly matched in the name registry.
View recorded company names
- CluePoints
- CluePoints INC
- CluePoints SA
- Cluepoints